EnGeneIC partners up to drive approval in the US.
Australian clinical-stage biopharm company EnGeneIC has entered a strategic partnership with the Singapore Institute of Advanced Medicine Holdings and Singapore Medical Incorporation to progress its clinical trial programs in Australia and the US.
The company is focused on its proprietary EnGeneIC Dream Vector nanocell technology for oncology and infectious disease applications. The EDVTM nanocell is the foundation of a first-in-class antibody nanocell drug conjugate platform for delivering a range of therapeutic payloads – drugs, siRNAs, miRNAs, adjuvants – via antibody-targeting a cancer cell’s surface, with minimal toxicity.
“The commercial deal will provide exclusive rights to SAM for sales of EDV therapeutics in Asia and net profits will be shared between the two companies, with EnGeneIC receiving a majority,” said the company’s announcement.
“In addition, EnGeneIC and SAM will collaborate on the development of EDV-based theranostics, by integrating imaging and treatment into a single platform.”
SMI has committed to providing funds for the capital expenditure requirements needed to complete the next phase of clinical tests to secure Food and Drug Administration approval in the US.
“Partnering with SAM and SMI marks a significant milestone for EnGeneIC, as we expand our footprint into our Asian neighbours”, said Dr Jennifer MacDiarmid, joint CEO of EnGeneIC.
“Our EDV technology is poised to transform cancer treatment and together with our partners’ expertise and resources which will facilitate cGMP-manufacturing capability and clinical trials, we are well-positioned to bring EDVs to a much broader patient population.”
